CJC-1295 no DAC 10mg

For research use only — not for human or veterinary use.

Analytical Verification (COA)

Each batch of CJC-1295 (no DAC) supplied by Grail Formula undergoes independent third-party laboratory verification to confirm compound identity, assay content, purity and microbiological safety.

Analytical testing for this batch was performed by Liquilabs s.r.o. (Czechia) using validated chromatographic and spectrometric techniques.

Batch: GF102025049

Key analytical results include:

• Assay Content (MOD GRF 1-29): 10.88 mg
• Identification – Retention Time: 0.994
• Identification – Spectrum: 997
• Purity: greater than 99.8 percent
• Bacterial Endotoxins: below 0.001 EU per mg
• Total Aerobic Microbial Count: not detected
• Total Yeast and Mold Count: not detected

Independent heavy metal screening confirmed no detectable levels of arsenic, cadmium, cobalt, lead, nickel, mercury or vanadium.

These analytical procedures ensure traceability, purity verification and laboratory-grade compound consistency.

Product Overview

CJC-1295 (no DAC), also known as MOD GRF (1-29), is a synthetic peptide frequently studied in laboratory environments investigating endocrine signalling and peptide-receptor interaction pathways.

The compound represents a modified analogue of growth hormone releasing hormone (GHRH) designed for research exploring hormone signalling and receptor-mediated regulatory systems.

This preparation contains 10 mg of high purity lyophilized peptide supplied in a sealed research vial. The lyophilization process preserves peptide stability and allows researchers to reconstitute the compound for controlled in vitro experimentation.

Because of its defined peptide sequence and stable analytical profile, CJC-1295 (no DAC) is widely referenced in experimental models exploring endocrine signalling and peptide-mediated receptor interactions.

Compound Overview

CJC-1295 (no DAC), chemically known as MOD GRF (1-29), is a modified analogue of growth hormone releasing hormone developed as a research compound to investigate endocrine signalling pathways.

The peptide interacts with growth hormone releasing hormone receptors in experimental laboratory models studying hormone regulation and peptide-mediated signalling processes.

Within biochemical research environments, the compound is frequently studied for its role in receptor-mediated signalling cascades and intracellular regulatory networks.

The defined peptide structure enables researchers to examine peptide-receptor interaction mechanisms and endocrine regulatory dynamics.

Historical Background and Scientific Context

Interest in hormone-regulating peptides expanded significantly during the late twentieth century as advances in molecular biology enabled researchers to analyse endocrine signalling systems at the receptor level.

Growth hormone releasing hormone analogues such as MOD GRF (1-29) were developed as experimental tools to study hormonal regulation and peptide-receptor signalling pathways.

These synthetic peptide analogues have since been widely referenced in laboratory research exploring endocrine signalling mechanisms and hormone-related regulatory systems.

Modern experimental models frequently utilise peptide analogues to investigate complex biochemical signalling pathways and receptor interactions.

Mechanistic Focus in Research

Within experimental laboratory environments, CJC-1295 (no DAC) is frequently studied in relation to endocrine signalling and peptide-receptor interaction pathways.

Research investigations commonly explore the compound in experimental models examining:

• Growth hormone releasing hormone receptor signalling
• Peptide-mediated endocrine signalling pathways
• Hormonal regulatory network modelling
• Intracellular signalling cascade dynamics
• Comparative peptide signalling research
• Receptor activation mechanisms
• Molecular endocrine pathway analysis

These experimental models allow scientists to investigate molecular regulatory mechanisms influencing endocrine signalling and peptide-receptor interactions.

Research Applications

In controlled research environments, CJC-1295 (no DAC) may be utilised in experimental models designed to explore endocrine signalling systems and peptide-mediated receptor pathways.

Examples of research applications include:

• Endocrine signalling pathway investigation
• Peptide-receptor interaction research
• Hormonal regulatory mechanism studies
• Cell signalling analysis
• Comparative peptide interaction modelling
• Molecular endocrine pathway research
• Controlled in vitro peptide signalling studies

Grail Formula Quality

Every Grail Formula research compound is produced under strict quality control procedures designed to support reliable laboratory experimentation.

Each batch undergoes independent analytical testing to verify:

• Compound identity
• Assay accuracy
• Purity confirmation
• Microbial safety
• Endotoxin levels
• Heavy metal screening
• Full batch traceability

All testing is performed by independent laboratories to ensure transparent verification and reproducible research material.

Research Use Limitation

• Used solely for in vitro experiments
• Not permitted for clinical trials involving humans
• Not permitted for human or veterinary administration
• Not permitted for investigational human use

• Verified and analysed with Liquilabs s.r.o. Czechia
• Above 99.8 percent purity with validated assay content
• No detectable heavy metals or microbial contamination
• Endotoxin below 0.001 EU per mg
• Batch GF102025049 – Published October 2025
• For research use only – not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.